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 Obesity is a major burden on public health, responsible for a myriad of 
complicated, dysfunctional metabolic phenotypes. In particular, the accumulation of fat 
outside of adipocytes is a serious area of concern.  Non-alcoholic fatty liver disease 
(NAFLD) is one such obesity-related disorder, about which little is known on a molecular 
level and for which successful treatment has yet to be established. My thesis lab took a 
genetic approach in zebrafish to identify new genes that participate in lipid metabolism in 
hope of finding mutants with ectopic lipid accumulation. A mutant with hepatic steatosis, 
or fatty liver, was identified. In this mutant, red moon (rmn), slc16a6a is nonfunctional, 
rendering hepatocytes unable to release ketone bodies during fasting. The trapped carbon 
atoms from these partially oxidized, short chain fatty acids critical to meeting the energy 
demands of the brain during starvation are diverted to de novo lipogenesis, and storage as 
triacylglycerol in cytoplasmic lipid droplets.  
My thesis work begins to build on known aspects of slc16a6a function. I started 
with a genetic screen to identify dominant modifying mutants and have discovered one 
such mutation, total eclipse of red moon (term), which suppresses the slc16a6a
-/-
 
phenotype. I have begun to determine its genomic position with RNA-seq mapping and 
have cloned several candidate genes. I have tested the candidates for mutations that could 
explain physiological insight into how hepatic steatosis can be attenuated. The hope is 





I have also established a platform to evaluate this gene’s role in a different disease 
context: cancer. Human melanomas show increased expression of SLC16A6. With Tol2 
transgenesis techniques, I made a transgenic construct that will be used to test whether 
this gene promotes cancer, measuring tumor growth and metastasis. This begins to look 
at whether ketone body uptake is a significant aspect of melanoma metabolism. The 
outcome of experiments done on the platform I have established could reveal a novel 
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Non-alcoholic fatty liver disease 
Obesity is an alarmingly prevalent and continually worsening problem worldwide. 
It also provokes and aggravates other metabolic disorders like Type 2 diabetes mellitus.  
Chronically high concentrations of circulating lipids cause a slew of problems, notably 
ectopic deposition of fat due to exhaustion of adipose tissue storage capacity (Schlegel, 
2012). Understanding the physiology of metabolic lipids is fundamental in the effort to 
reverse obesity and its related pathologies. We put particular effort behind discovering 
new genes that control lipid transport, storage, and consumption throughout the 
vertebrate body.  
A problem arising from high fat intake is non-alcoholic fatty liver disease 
(NAFLD). Worldwide, NAFLD affects 30% of adults (Gastaldelli et al., 2009). It 
commonly accompanies atherosclerosis (Targher et al., 2010) and a link with insulin 
resistance is rapidly becoming apparent (Cohen et al., 2011). The initial stage of NAFLD 
is hepatic steatosis, in which cytoplasmic triacylglycerol is deposited in hepatocytes. 
Steatosis can progress into non-alcoholic steatohepatitis (NASH), where hepatocytes 
begin to swell and undergo cell death, recruiting immune cells and initiating fibrosis. 





tissue (collagen) and stellate cells. Finally, cirrhosis may  give rise to hepatocellular 
carcinoma (Cohen et al., 2011).  
A complete understanding of the molecular pathways underlying hepatic steatosis, 
and its progression into NASH, and cirrhosis remains to be established. NAFLD is 
approximately 39% heritable (Schwimmer et al., 2009). Several sequence variations that 
show correlation with hepatic steatosis in humans have been identified. One variant 
showing the strongest association with fatty liver occurs in PNPLA3, a triglyceride 
hydrolase and transacylase (Romeo et al., 2008). It is unclear how the mutation, I148M, 
causes an accumulation of fat in hepatocytes. Various other studies have found more 
susceptibility loci containing genes such as NCAN, GCKR, LYPLAL1, APOC3, and 
PPP1R3B (Cohen et al., 2011). Variants in these suggest several mechanisms to promote 
fatty liver, including down-regulation of lipases or up-regulation of fatty acid synthesis. 
The molecular mechanisms for how these variants contribute to hepatic lipid 
accumulation have not been elucidated.  
 
Solute carrier family 16a, member 6a 
Through a forward genetic screen to identify lipid storage defects, our lab 
previously uncovered a recessive mutation which causes hepatic steatosis, red moon 
(rmn).  Homozygous rmn larvae develop this phenotype when they begin fasting, i.e. 
after the entire maternally deposited yolk lipid supply has been consumed, typically six 
days post-fertilization (dpf). Increased triacylglycerol in the liver relative to wild-type 
animals can be visualized using Oil Red O (ORO), a neutral lipid stain (Figure 1). With 












the molecular lesion is a retro-transposable element insertion in the second exon of 
slc16a6a, which encoded an orphan plasma membrane monocarboxylate transporter 
(formerly MCT7). The slc16a6a
-/-
 mutant phenotype can be rescued by ubiquitous or 
liver-specific re-expression of wild-type slc16a6a, by liver-specific expression of the 
human ortholog SLC16A6, or by re-feeding fasted animals at any time point after 6 dpf 
(Hugo et al., 2012). 
Other MCTs have been thoroughly studied. For MCT1 through 4, the most widely 
characterized substrate is lactate (Halestrap, 2013a). However, new evidence has shown 
that MCT1 also imports ketone bodies; a causal link has been found between MCT1 
deficiency and severe recurrent ketoacidosis in children (van Hasselt et al., 2014). When 
heterologously expressed in Xenopus oocytes, zebrafish Slc16a6a transported β-
hydroxybutyrate across the cell membrane (Hugo et al., 2012). -hydroxybutyrate is the 
major ketone body species produced during fasting (Cahill, 2006). The following model 
was then proposed and tested. If slc16a6a is mutated, then individuals are defective in 
releasing ketone bodies from the liver, effectively trapping ketones inside hepatocytes. 
The carbon atoms from liver-trapped ketone bodies in slc16a6a
-/-
 mutant livers thus 
Figure 1. Whole mount staining of fixed 6dpf larve stained with Oil Red O 






become reincorporated into fatty acids which are stored as triacylglycerol in cytoplasmic 
lipid droplets (Hugo et al., 2012).  
 
Approach for identification of new hepatic lipid metabolism genes 
My goal has been to use the slc16a6a
-/-
 mutants to find genes with which 
slc16a6a interacts by means of a modifier screen. We anticipated two types of mutants: 
suppressors, those with lessened hepatic steatosis, and enhancers, those with an increased 
hepatic steatosis (or an advanced pathological phenotype such as cirrhosis). Aside from 
identifying genetic interactions with slc16a6a, I also wanted suppressor mutations for 
their potential to reveal new genes that relieve steatosis. These factors, in both the 
suppressor and enhancer categories, could prove to be useful targets for therapeutics to 
combat NAFLD.  To map the dominant mutations we identified, we used a whole 
transcriptome-based approach called Mutation Mapping Analysis Pipeline for Pooled 
RNA-Seq (MMAPPR) (Hill et al., 2013). The technique involves comparing wild-type 
and mutant whole transcriptomes (RNA-seq), searching for single nucleotide 
polymorphisms (SNPs) that are linked to the mutant locus. Candidate genes in the linked 
region can then be selected and tested directly.   
 
Monocarboxylate transporters in cancer 
In exploring publicly available clinical data pertaining to SLC16A6, we found a 
potential new disease context in which to investigate the function of this gene. Using the 
Oncomine interface, gene expression data show that SLC16A6 expression is increased in 






























Figure 2. Affymetrix microarray of human skin samples. Oncomine query of 
dataset from Talantov et al. 2005 .Relative SLC16A6 expression is shown in 
increasing order. Dark blue bars represent melanoma samples; light blue bars 
represent normal skin in A and non-cancerous melanocyte lesions in B. Average fold-
increase in abundance in tumors compared to skin: 27.024 (p = 6.54 x 10-7); compared 





lesions (nevi), and 7 normal skin tissue samples were analyzed. Compared to normal 
skin, SLC16A6 levels in primary melanoma samples were approximately 27-fold higher 
(top 4% of overexpressed genes) and compared to benign nevi, approximately 8-fold 
higher (top 2% of overexpressed genes) (Talantov et al., 2005). As the pre-cancerous 
lesions do not have significantly increased SLC16A6 compared with normal melanocytes, 
it is reasonable to hypothesize it presenting a growth advantage to lesions which enables 
malignancy. 
Melanoma, despite affecting only 76,000 people in the US (ACS estimate for 
2014), accounts for the highest portion of skin cancer deaths (Gyrylova et al., 2014). It is 
particularly prone to rapid growth and metastasis as skin cell turnover is extremely fast. I 
sought to assess whether increased SLC16A6 expression in melanoma contributes to 
aspects of its malignancy, including onset of tumor formation, invasion, and metastasis. 
Following this, I also planned to elucidate its mechanism of promoting cancerous growth.  
My studies are informed by recent work placing monocarboxylate transporters as 
having an important role in metabolite transport for cancer cells. On a fundamental level, 
cancer cells rely heavily on anaerobic glycolysis for energy and synthetic substrates, 
which consequently generates large quantities of pyruvate and lactate. For this reason, 
lactate transporters of the SLC16 family are in many cases expressed at higher levels in 
cancerous cells than others, particularly SLC16A1 (or MCT1) (Pinheiro et al., 2014; 
Kennedy and Dewhirst, 2010). Further, certain subpopulations of tumor cells have been 
shown to take up lactate as a fuel source, insinuating a symbiotic “lactate shuttling” 
system between subpopulations and between tumor and stroma (Kennedy and Dewhirst, 





or pyruvate. However, with the evidence for β-hydryoxybutyrate transport in zebrafish, I 
favor a model in which ketone bodies are taken up and used by cancer cells. Ketone 
bodies could be advantageous to cancer cells to feed fatty acid synthesis and thus supply 
an increased demand for lipids (Baenke et al., 2013). 
I have worked to establish a transgenic zebrafish line in with which SLC16A6 
involvement in cancer can be explored. Future experiments using this system can add 
another level to our current understanding of tumor metabolism. Supporting this, the 
human SLC16A6 protein can be studied in vitro to discover details about its substrate 






















total eclipse of red moon 
 
Genetic screening for dominant modifiers of slc16a6a
-/-
 
 In order to understand how liver lipid mass is controlled during fed and fasted 
states, a genetic screen was used to identify dominant mutations that modify the 
slc16a6a
-/- 
phenotype (Figure 3A). slc16a6a-/- males were mutagenized with N-ethyl-N-
nitrosourea (ENU). The F0 animals were crossed with slc16a6a
-/- 
females, yielding F1 
families of at least 60 individuals each. Each F1 animal was crossed to a slc16a6a
-/-
 mate 
and F2 offspring were screened for enhancement or suppression of the slc16a6a
-/- 
phenotype. To do this, clutches of 7 dpf larvae were fixed and stained with Oil Red O 
(ORO) to visualize neutral lipids in livers. As I sought dominant mutations, I looked for 
heterozygous carriers that produced clutches in which half of the F2 offspring show the 
modified phenotype and half show normal slc16a6a
-/-
 liver staining. 
I identified an F1 individual whose offspring exhibit the appropriate pattern for 
carrying a dominant suppressor allele: half showed the slc16a6a
-/-
 phenotype and half 
showed reduced ORO staining in the liver (Figure 3A: “F2 Dominant Suppressors”). I 
have named this mutation total eclipse of red moon (term). I then crossed this carrier to a 
mapping line homozygous for the slc16a6a
-/-
 mutation, and sorted live offspring by  

























490 nm excitation) (Fowler and Greenspan, 1985). 
 
Mutation mapping analysis using RNA-Seq 
I crossed the F1 heterozygous term carrier with an individual from a mapping 
strain (WIK) slc16a6a
-/- 
to create a mapping panel of F2 individuals. After sorting as term 
carrier (+/mut) or non-carrier (+/+) from this clutch, the two phenotypes were split into 3 
smaller pools (18 each) from which total RNA was extracted. From these samples, a 
cDNA library was prepared and sequenced on an Illumina HiSeq2000 next generation 






Figure 3. total eclipse of red moon. A. red moon modifier screening strategy. The red 
moon stock originated on an AB/Singapore genetic background. A mapping strain was 
generated for the F
1
 outcross by crossing the rmn mutation into a polymorphic WIK 
strain. B. Oil Red O stained term mutant. 7 dpf larvae imaged under bright field light 
on a Leica DFC 310 FX stereo microscope. 
























 The RNA-Seq dataset from these phenotypic pools was used to map the mutation 
with Mutation Mapping Analysis Pipeline for Pooled RNA-Seq (MMAPPR) (Hill et al., 
2013). The term mutation was mapped to a 5.7 megabase (Mb) region on Chromosome 7 
spanning from base 16,848,097 to 22,579,615 (Figure 4). This peak contains a total of 




differential expression analysis was performed for all genes on chromosome 7, but none 
showed significantly different expression levels between pools (data not shown).  
 
Candidates for the term gene 
Unfortunately, among the SNPs detected using MMAPPR that fell in this region, 
we did not find one that appeared causal. I have selected four promising candidate genes 
to test, which are summarized in Table 1.   
 
rab1ba 
One term mutant candidate gene is rab1ba. In humans, Rab1b is a regulator 
vesicle traffic in the secretory pathway (Plutner et al., 1991). Through its interaction with  
Arf1, a protein also involved in vesicle assembly and suggested to act in very low density 
lipoprotein (VLDL) particle secretion, Rab1b may have a connection with lipoprotein 
particle  packaging as well (Mochizuki et al., 2013). It is possible that a gain-of-function 























animals by enhancing VLDL secretion. Alternatively, a loss-of-function mutation in 
Rab1b, may disrupt autophagy, or cellular macromolecular recycling (Mochizuki et al., 
2013), during starvation. If rab1ba function is diminished, fewer ketogenic amino acids 



























Figure 4. Single nucleotide polymorphisms segregating with term are clustered on 
chromosome 7. Throughout the assembled transcriptome, Euclidean distance scores at 
each nucleotide position were calculated, raised to the second power, plotted and fitted 
to a Loess curve. A: Entire transcriptome assembly, B: close-up of chromosome 7. 















Protein function Hypothetical mechanism of 








GTPase essential for vesicle 
formation in early secretory 
pathway 
Gain of function enhances 
VLDL secretion, allowing  
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Dominant negative or 
haploinsufficient phenotypes 
impair import of amino acid 




The human ortholog SLC7A7 encodes the light chain of the y+L system, a protein 
essential for intracellular amino acid transport as a subunit of LAT1 (SLC3A2), the large 
neutral amino acid transport complex in the plasma membrane (Moger et al., 2012). Loss 
of function mutations in human SLC7A7  cause lysinuric protein intolerance (Borsani et 
al., 1999). Lysine is a ketogenic amino acid (Cahill, 2006).  
 
 
Table 1: Candidate genes in the term-linked region. Genome positions based on 









Human SLC3A2 is the heavy chain of the y+L system, comprising SLC7A7 and 
SLC3A2. Disruption of slc3a2 would make sense in the context of the term phenotype 
for the same reason as its counterpart slc7a7 would. A caveat to this hypothesis is that 
zebrafish in situ experiments has only found expression in the nervous system, pancreas, 
and yolk syncytial layer of early-stage embryos (Moger et al., 2012), while Human data 
indicates that the ortholog, Slc3a2, is expressed in the human liver (MOPED and PaxDb). 
However, this does not rule out cell-non-autonomous effects of a mutated slc3a2. 
 
slc16a13 
 This gene was our strongest candidate, as it is encodes an orphan 
monocarboxylate transporter. The most obvious hypothesis for how mutations in 
slc16a13 suppress hepatic steatosis in slc16a6a
-/-
 animals is a gain-of-function scenrario, 
in which Slc16a13 exports -hydroxybutyrate. Interestingly, SNPs in the SLC16A13 
locus (which includes the neighboring orphan MCT gene SLC16A11) were identified in 
two separate genome-wide association studies (GWAS) as conferring  risk to the 
development of Type 2 Diabetes Mellitus (Hara et al., 2014; Williams et al., 2014). 
 
Results 
I cloned slc16a13 and rab1ba cDNAs from term mutants. Upon Sanger 
sequencing, no coding differences were observed when compared with non-carriers (not 






Materials and methods 
Mutagenesis and screening 
slc16a6a
-/-
 adult males were exposed to N-ethyl-N-nitrosourea (ENU). These were 
each out-crossed to a slc16a6a
-/-
 female, the offspring of which were raised and 
subsequently outcrossed again to a slc16a6a
-/-
 mate (see Figure 3A). These F2 individuals 
were screened for liver steatosis by fixing in 4% formaldehyde at 7 dpf (≥1 hr), staining 
with Oil Red O (1 hr, shaking), and rehydrating in phosphate buffered saline (PBS). 
Images of F2 individuals were taken under bright field illumination on a Leica DFC 310 
FX stereo microscope after mounting the fixed and ORO-stained larvae in 1% low melt 
agarose. 
 
Live phenotype sorting 
Live F2 offspring of term
+/mut
 x WIK slc16a6a
-/-
 were sorted at 7 dpf using Nile 
Red stain. Larvae were incubated in 0.5 μg/mL Nile Red for 30 min in the dark and 
anaesthetized with tricaine. Larvae were observed under fluorescence on a Leica DFC 
310 FX stereo microscope using GFP range excitation (450-490 nm) and sorted 
according to intensity of yellow liver staining (with WIK slc16a6a-/- and WIK 
slc16a6a+/+ from non-mutagenized parents for reference).  
 
RNA-Seq sample preparation and MMAPPR 
 After Nile Red sorting, three pools (n=18) of each phenotype were collected and 
homogenized. Total RNA was isolated from the homogenates using the RNeasy RNA 





facility, where a cDNA library was generated and sequenced with an Illumina Hi-Seq 
2500 instrument (described in the following two subsections). In silico analysis on RNA-
Seq data using MMAPPR software was performed by Jonathon Hill of the Joseph Yost 
laboratory at the University of Utah as described in (Hill et al., 2013). Library 
construction was performed using the Illumina TruSeq RNA Sample Preparation Kit v2 
(RS-122-2001 and RS-122-2002) as described in the next two subsections taken from the 
Univeristy of Utah’s High Throughput Genomics Core Facility web-based system named 
GNomEx (https://hci-bio-app.hci.utah.edu/gnomex).  
 
Library construction 
Briefly, total RNA (100 ng to 4 ug) is poly-A selected using poly-T oligo-attached 
magnetic beads.  Poly-A RNA is eluted from the magnetic beads, fragmented and primed 
with random hexamers in preparation for cDNA synthesis.  First strand reverse 
transcription is accomplished using Superscript II Reverse Transcriptase (Invitrogen 
cat#18064-014).  Following second strand synthesis, the cDNA is converted to blunt-
ended fragments with 5'-phosphates and 3'-hydroxyl groups using a combination of 
enzymes that perform fill-in reactions and exhibit exonuclease activity.  An A-base is 
added to the blunt ends as a means to prepare the fragments for adapter ligation and block 
concatamer formation during the ligation step.  Adapters containing a T-base overhang 
are ligated to the A-tailed DNA fragments.  Ligated fragments are PCR-amplified (12 
cycles) and the amplified library is purified by Agencourt AMPure XP beads (Beckman 
Coulter Genomics cat#A63881).  The concentration of the amplified library is measured 





Agilent 2200 Tape Station using a D1K (cat# 5067-5361 and 5067-5362) or a High 
Sensitivity D1K (cat# 5067-5363 and 5067-5364) assay to define the size distribution of 
the sequencing library.  Libraries are adjusted to a concentration of approximately 10 nM 
and quantitative PCR is performed using the KapaBiosystems Kapa Library Quant Kit 
(cat# KK4824) to calculate the molarity of adapter ligated library molecules.  The 




Sequencing libraries (18 pM) were chemically denatured and applied to an 
Illumina TruSeq v3 single read flowcell using an Illumina cBot.  Hybridized molecules 
were clonally amplified and annealed to sequencing primers with reagents from an 
Illumina TruSeq SR Cluster Kit v3-cBot-HS (GD-401-3001).   Following transfer of the 
flowcell to an Illumina HiSeq instrument (HCS v2.0.12 and RTA v1.17.21.3), a 50 cycle 
single read sequence run was performed using TruSeq SBS v3 sequencing reagents (FC-
401-3002).  
 





 RNA samples were reverse transcribed, providing a 
template for polymerase chain reaction (PCR) amplification of candidate genes. These 
two steps were achieved with a SuperScriptIII/Platinum Taq combination RT-PCR kit 
(Invitrogen/Life Technologies). Products were electrophoresed in a 1% agarose gel, 





into a linearized pGEM®-T Easy Vector (Promega) with T4 DNA ligase (Promega) and 
the resulting plasmids were transformed into NEB-10β competent cells (New England 
Biolabs). These were plated on LB agar plates with ampicillin, x-gal, and IPTG for 
blue/white selection of colonies containing successful recombinants. Plasmids were 
isolated from white colonies and submitted for Sanger Sequencing at the University of 
Utah Sequencing core facility with primers T7 and SP6. A list of all primer sequences 

























TRANSGENIC EXPRESSION OF HUMAN SLC16A6 
 
Human SLC16A6 in mammalian cells 
 In order to characterize human SLC16A6, I first turned to stable transfection into 
mammalian cells to achieve protein expression, with the help of Nicola Longo and 
colleagues. I transfected a plasmid encoding a SLC16A6-EGFP fusion construct into 
Chinese hamster ovary (CHO) cells, hoping to obtain clones with green fluorescent 
plasma membranes (Figure 5A). When visualized with confocal microscopy, however, 
both empty pEGFP-N1 vector and SLC16A6-EGFP transfected cells showed diffuse 
cytoplasmic green fluorescence (Figure 5B). The fusion protein may not have been 
targeted correctly to the plasma membrane.  
 
Transgenic SLC16A6 zebrafish 
Next, I generated a transgenic construct to express SLC16A6 without a large 
epitope tag that might interfere with trafficking (Figure 6A). Using the promoter from 
the liver-specific gene fabp10a to drive its expression, I generated a transgenic construct 
with SLC16A6 preceded by the zebrafish consensus Kozak sequence and enhanced green 
fluorescent protein (EGFP) on the C-terminus: Tg(fabp10:SLC16A6,EGFP). A viral 2A 





















liberate the EGFP protein from SLC16A6: during translation, ribosomes fail to make a 
peptide bond between proline and glycine in the 2A sequence, effectively “cleaving” the 
nascent polypeptide (Diao and White, 2012). This strategy allows expression of a marker 
for translation of SLC16A6 without the complication of a large protein tag.  
Upon injection of this construct into one cell slc16a6a
-/-
 embryos and upon 
screening for EGFP, mosaic expression of EGFP in the liver was evident (Figure 6B). 
Note that the yellow fluorescence in the intestine and gallbladder is due to bile. To assess  
Figure 5. A. Strategy for transgenic expression of human SLC16A6 in mammalian 
cells. A. Mammalian over-expression construct for SLC16A6 B. From Xue Yin, Nicola 
Longo Lab: cultured CHO cells transfected with EGFP-tagged SLC16A6 in cultured. 





























whether SLC16A6 was expressed and functional, I injected the  
Tg(fabp10:SLC16A6,EGFP) construct into slc16a6a
-/- 
embryos and determined that 
hepatic steatosis had been rescued (Figure 6C). Note that this rescue is partial, as the 
transgene is mosaically expressed: the ORO staining is limited to ventral portions of the 
liver. I have also attempted to see SLC16A6 by immunodetection in these green-livered 
larvae (western blot remains to be optimized). 
 
Figure 6: Transgenic expression of SLC16A6 in zebrafish liver A. Schematic 
representation of Tol2 destination vector containing the transposable cassette 
fabp10:SLC16A6,EGFP. B. 7 dpf slc16a6a
-/- 
larvae injected with the  
fabp10:SLC16A6,EGFP. Top: uninjected, bottom: injected with transgenic construct. 
Images taken on a Leica DFC 310 FX Stereo microscope using GFP range excitation 
(450-490 nm). Yellow autofluorescence is due to fats in gut lumen and gallbladder. C. 











Melanoma studies with SLC16A6 
The SLC16A6,EGFP cassette will be subcloned into miniCoopR and the resulting 
plasmid can be used to study modifiers of melanomagenesis when injected into zebrafish 




The melanoma fish line contains one transgene (mitfa:BRAF
V600E/V600E
) and two 




).  The human BRAF transgene, driven by 
the promoter of melanocyte-specific mitfa, reflects the most common mutation linked to 
melanoma, which causes excessive activity of the mitogen-activated protein kinase 
kinase (MAPKK) BRAF. As an additional insult to observe rapid development and 
progression of melanoma, this is done in a p53 null background. Additionally, deletion of 
mitfa prevents melanin biosynthesis (Ceol et al., 2011). This mutation is present so that 
additional genes may be introduced on a miniCoopR construct carrying functional mitfa, 
so that the coincidence of pigment production rescue and expression of the transgene of 
interest can be achieved in a cell-autonomous manner (Figure 7).   
With my successfully expressing SLC16A6 construct, the cDNA can be subcloned 









embryos. From the microarray data (Talantov et al., 2005), it seems likely that transgenic 
expression of SLC16A6 will be advantageous to melanoma tissue. Survival, tumor onset, 
growth, and metastasis can be measured as described previously (Ceol, 2011). Compared 
to control animals, I expect accelerated tumor incidence and/or growth and a 







microarray analysis had no information regarding whether samples belonged to 
metastatic tumors, the question of whether SLC16A6 promotes metastasis remains 
unpredictable. 
If SLC16A6 does enhance the aforementioned cancer phenotypes, this experiment 
will also tell us whether the effects are cell-autonomous. If only the melanin-producing 
populations of melanocytes worsen upon SLC16A6 introduction, then the gene only 
benefits tumor tissue in which it is expressed. If both pigmented and un-pigmented 
tumors increase in incidence, growth, or metastasis, then SLC16A6 expression is 
promoting a cancerous environment on a more global scale.  
                         
 
 
Figure 7. Transgenesis strategy to test SLC16A6 involvement in melanoma. A 
“candidate oncogene” (SLC16A6 in my case) can be put under the control of the mitfa 
promoter in tandem with a functional mitfa cDNA. The two gene cassettes are 
between transposition sites, allowing their genomic insertion when the plasmid is 







animals, melanocytes expressing this construct will regain the capacity 
for melanin production. Once mature, survival, time of tumor onset, and metastasis 





Biochemical characterization of human SLC16A6 
Because human SLC16A6 functionally rescues slc16a6a
-/-
 animals, we are 
interested in characterizing the human protein and exploring further roles in human 
disease. We hope to successfully express this cassette in mammalian cells in order to 
identify substrates and determine kinetic parameters for SLC16A6 transport. I 
hypothesize that, as with Slc16a6a, the human protein also shows a preference for β-
hydroxybutrate. On a nonquantitative level, voltage clamp experiments can be done to 
determine whether incubation with β-hydroxybutyrate incubation generates an inward 
current in Xenopus oocytes expressing human SLC16A6 (Hugo et al., 2012). Further, 
mammalian cells expressing SLC16A6 can be assayed for the rate at which they take up a 
variety of MCT substrates. This can be done in collaboration with Nicola Longo, using 
his established cluster tray method for testing cationic transport substrates (Ardon et al., 
2010; Scaglia et al., 1999). Β-hydroxybutyrate can be detected by an enzymatic assay 
using 3-hydroxybutyrate dehydrogenase, whose catalysis produces NADH which can be 
measured with a colorimetric probe (Cayman Chemicals). From time course experiments, 
kinetic parameters can be determined according to a Michaelis-Menten model (Scaglia et 
al., 1999). An important note regarding substrate specificity is that β-hydroxybutyrate 
accounts for 75% of circulating ketone bodies while acetoacetate makes up the 
remainder. Thus, acetoacetate transport should also be measured, though no simple 
detection assay is currently available. It may be advantageous to cancer cells to pump out 
lactate or pyruvate, so these should be tested as well. The outcome of these experiments 
could provide additional insights into melanoma tumor metabolism. Cancer cells in 





need for partially oxidized substrates (i.e. ketone bodies). Alternatively, it is likely that 
SLC16A6 transports lactate, which may be an advantage for proliferating tumor cells, 
which produce an excess of lactate from glycolysis due to minimal mitochondrial 
oxidation (Draoui and Feron, 2011).  
 
Materials and methods 
SLC16A6 transgensis in mammalian cell culture 
 SLC16A6 cDNA was amplified off of a plasmid already containing SLC16A6 
named “pME-HuSLC” made by Lourdes Cruz-García in 2011 (Hugo et al., 2012) using 
primers “HsSLC-F_Xho” and “HsSLCnostop-R” containing sites for XhoI and SacII 
restriction endonucleases, respectively. The resultant PCR product and pEGFP-N1 vector 
(Clontech) were digested with Xho I and SacII (New England Biolabs). The vector 
digestion product was dephosphorylated using Calf Intestinal Alkaline Phosphatase 
(Promega). The insert and vector (3:1 molar ratio) were ligated together with T4 DNA 
ligase (Promega), and transformed into NEB 10β competent cells (New England 
Biolabs). Plasmids (pEGFP-N1-SLC16A6) were isolated from bacterial clones and the 
presence of the insert was verified by Sanger sequencing using primers “seq_pEGFPN1-
F” and “seq_pEGFPN1-R”. 
 The following was done by Xue Yin of Nicola Longo’s laboratory at the 
University of Utah. Each plasmid, pEGFP-N1-SLC16A6 and empty pEFGP-N1 vector, 
was transfected into Chinese Hampster Ovary (CHO) cells using lipofectamine. Selection 
for stable clones with integrated SLC16A6 cassette was performed using neomycin. 





Transgenic zebrafish expressing SLC16A6 
This expression plasmid was constructed using a standard Gateway cloning 
strategy with materials from Invitrogen/Life Technologies. Specific for zebrafish 
transgenesis is the “Tol2 kit” developed by Kwan and colleagues (Kwan et al., 2007). I 
amplified SLC16A6 using primers “attB1-SLC16A6 zebrafish kozak” and “attB2R-
SLC16A6 C-term 2AEGFP” off of pME-HuSLC. The resultant PCR product excludes 
the stop codon and includes the zebrafish consensus Kozak sequence (GCAACC) 
immediately upstream of the start codon. This PCR product was electrophoresed on a 1% 
agarose gel, excised using a gel extraction kit (Bioneer), then recombined into pDONR-
221 with BP clonase (Invitrogen/Life Technologies) to generate pME-zSLC16A6. Clones 
were sequenced with M13F and M13R to verify presence of insert. pME-zSLC16A6 was 
recombined with p5E-fabp10a (Lourdes Cruz-García, University of Portsmouth) and 
p3E-2AEGFP (Kristen Kwan, University of Utah) into pDestTol2pA2 using LR clonase 
(Invitrogen/Life Technologies). The combined insert of the final destination vector 
(Figure 6A) was sequenced using primers seq_pDestTol2pA2_B4, seq_fabp10a_B1, 
seq_SLC16A6nostop_B2, seq_2AeGFP_B3.  
 The transgenic construct was combined with Tol2 transposase capped and tailed 
mRNA as described previously (Kwan et al., 2007). This cocktail was injected into one-
cell slc16a6a
-/- 
embryos. Embryos were raised to 7 dpf and then screened for hepatic GFP 
expression under fluorescence on a Leica DFC 310 FX stereo microscope using GFP 
range excitation (450-490 nm). Individuals showing hepatic GFP expression were 






fluorescent light or fixed in formaldehyde, stained with ORO (as described in the above 




























PCR PRIMERS AND PARAMETERS 
 
RT-PCR amplification of term candidate genes 
rab1ba 5UTR 2     TCAAGTGACTGGATCCAACG   
rab1ba 3UTR 2     GGACTTTACGTACAGGGGGC 
 
Program:         Temp (°C)        Time (min:sec) 
cDNA synthesis     55               30:00 
Initial Denaturation     94               02:00 
Denaturation                 94               00:15 
Annealing                 60               00:30 
Extension                 68               01:00 
Repeat steps 3-5 x 45   
Final extension     68               05:00  
 
slc16a13 5'UTR 2     GAACCTTCCGCACGTGTAGT   
slc16a13 3'UTR 2     TGCTGCTTTTGAAACTCCAA  
 
Program:              Temp (°C)        Time (min:sec) 
cDNA synthesis      55            30:00 
Initial Denaturation      94            02:00 
Denaturation          94            00:15 
Annealing                  60            00:30 
Extension                  68            02:00 
Repeat steps 3-5 x 45   
Final extension      68            05:00 
 
 
Primers for SLC16A6 amplification for  
expression in CHO cells 
 
HsSLC-F_Xho ggggccctcgaggCAGGCTATGACCCAAAA 








Program:                     Temp (°C)   Time (min:sec) 
Initial Denaturation           95      02:00 
Denaturation                       95      00:30 
Annealing                       53      00:30 
Extension                       72      01:30 
Repeat step 2-5 x 30 
Final extension            72      05:00 
  
Primers for SLC16A6 amplification for expression in zebrafish 
attB1-SLC16A6 zebrafish Kozak
 GGGGACAAGTTTGTACAAAAAAGCAGGCTgcaaccATGACCCA   
attB2R-SLC16A6 C-term 2AEGFP
 GGGGACCACTTTGTACAAGAAAGCTGGGTaTACCGGCT  
 
Program:           Temp (°C)       Time (min:sec) 
Initial Denaturation        98              01:00 
Denaturation                    98              00:10 
Annealing             55              00:15 
Extension                    72              00:50 
Repeat steps 2-4 x 30 
Final extension        72              05:00 
 
 
Sanger sequencing primers 
 
T7                                              TAATACGACTCACTATAGGG 
SP6                                               ATTTAGGTGACACTATAG 
seq_pEGFPN1-F               CATGGTCCTGCTGGAGTTCGTG    
seq_pEGFPN1-R               CCTCTACAAATGTGGTATGGCTG    
M13F                                       TGTAAAACGACGGCCAGT   
M13R                                     CAGGAAACAGCTATGACCATG   
seq_pDestTol2pA2_B4   GGCAGCAGTGCAATTCTAACAG   
seq_fabp10a_B1               GGTCATTGACTGAACTCCTCT   
seq_SLC16A6nostop_B2   CAAAGGTAGTGAGCCATCGT      
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